← Leaderboards
Qin Yu
University Of Pennsylvania
$7,039,104
Attributed
$7,039,104
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $817.7K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,039,104 · 5
By mechanism
R01$7,039,104 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Mark I Greene$18,808,015
- Alice S Chen-Plotkin$18,977,934
- Robert H. Silverman$18,272,403
- Sarah Ching-Lan Hsu$106,917
- Gary A. Koretzky$15,998,977
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistMolecularIn VivoPlayResistanceMediatingPathway InteractionsClinically RelevantResponseIn VitroTumorSignal PathwayGrowthTherapeutic AgentsResearch StudyCell ProliferationApoptosisBiologicalLigandsInnovationBiochemicalReceptor Protein-Tyrosine KinasesBinding (Molecular Function)Neoplastic Cell
Grant awards (24)
Developing therapeutics against resistance to the androgen-deprivation therapy$387,731
R01 · FY2020 · CA · contact PI
Developing therapeutics against resistance to the androgen-deprivation therapy$376,098
R01 · FY2019 · CA · contact PI
Developing therapeutics against resistance to the androgen-deprivation therapy$387,731
R01 · FY2018 · CA · contact PI
Developing therapeutics against resistance to the androgen-deprivation therapy$387,731
R01 · FY2017 · CA · contact PI
Developing therapeutics against resistance to the androgen-deprivation therapy$387,731
R01 · FY2016 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$339,000
R01 · FY2015 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$390,364
R01 · FY2014 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$18,455
R01 · FY2013 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$379,946
R01 · FY2012 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$379,946
R01 · FY2011 · CA · contact PI
Merlin Signal in Glioma: Therapeutic Agents and Targets$349,048
R01 · FY2010 · CA · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$292,138
R01 · FY2010 · CA · contact PI
CD44 Antagonists in Targeted and Combinational Therapy for Glioblastoma$176,526
R01 · FY2010 · CA · contact PI
Merlin Signal in Glioma: Therapeutic Agents and Targets$349,048
R01 · FY2009 · CA · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$292,138
R01 · FY2009 · CA · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$292,138
R01 · FY2008 · CA · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$292,138
R01 · FY2007 · CA · contact PI
Angiopoietins in Angiogenesis$304,607
R01 · FY2006 · HL · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$297,917
R01 · FY2006 · CA · contact PI
Angiopoietins in Angiogenesis$4,944
R01 · FY2006 · HL · contact PI
Anti-cancer Activity and Mechanism of ADAMTS-1 Fragments$2,729
R01 · FY2006 · CA · contact PI
Angiopoietins in Angiogenesis$317,000
R01 · FY2005 · HL
Angiopoietins in Angiogenesis$317,000
R01 · FY2004 · HL
Angiopoietins in Angiogenesis$317,000
R01 · FY2003 · HL